Metabolic & Cardiometabolic
metabolic/bariatric surgery causes type 2 diabetes remission
In plain terms: Does metabolic surgery cause type 2 diabetes remission?
Strong support Metabolic & Cardiometabolic
Part of: 🩺 bariatric / metabolic surgery
RefutedContestedStrong support
consensus score 0.84
Yes—RCTs and cohorts show surgery causes far higher T2D remission than medical therapy, but remission wanes over time and relapse is common.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
39 support 0 contradict 0 tested null 5 mixed · 44 sources, 37 independent groups
The evidence (44)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Tan WL et al 2026 · study_type: observational | observational | mixed | low | Retrospective cohort, n=1478 (Malaysia), formal remission could not be ascertained (no medication data); at 1yr, 80.9% of diabetics reached HbA1c<6.5% and 47.8%<5.7%, but 5-year subgroup (7.2% of cohort) showed selective retention/attrition |
| Ikramuddin 2018 · JAMA | RCT | mixed | high | Diabetes Surgery Study 5yr: RYGB improved composite targets but durability waned—triple-endpoint benefit not sustained at 5yr. |
| Cui B et al 2026 · study_type: meta-analysis | meta-analysis | mixed | high | Network meta-analysis of 10 RCTs, n=1004, >=10-year follow-up, MBS vs medical therapy. Only BPD/DS achieved a statistically significant advantage over medical therapy for diabetes remission (OR=24.91); other procedures showed potential but |
| Galvan JAA et al 2026 · Journal of Multidisciplinary Healthcare | observational | supports | moderate | Retrospective cohort, n=180 (LSG/RYGB), Malaysia, 5-year follow-up. HbA1c fell from 6.37% to 5.62% (GEE p<0.001) alongside major BMI reduction; exploratory cost-effectiveness analysis also favorable. |
| Lau ST et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=236 (surgery 115, medical 121), Malaysia, up to 5yr follow-up. Overall diabetes remission 56.5% in bariatric group; remission strongly predicted by disease severity (mild-moderate IMS 77.5% vs severe 8.6%), not proce |
| Ochs V et al 2026 · study_type: observational | observational | supports | moderate | Multicenter retrospective cohort, n=9652 (RYGB/SG, 11 European centres), external validation cohort from Sweden. ML classifier predicted T2D remission up to 5yr with high discrimination (F1 0.88-0.89); underlying cohort data reflect real re |
| Nor Hanipah Z et al 2026 · Obesity Surgery | observational | supports | low | Retrospective cohort, n=76 adolescents/young adults (Louisiana), mean follow-up 16 months. Diabetes remission occurred in 94% (15/16) of those with follow-up data. |
| S Abdelrahim H et al 2026 · Obesity Surgery | observational | supports | moderate | Retrospective cohort, n=115, revisional OAGB after failed restrictive procedures, 5-year follow-up. T2DM remission rate 70.8% at 5 years. |
| d10-3389-fendo-2026-1849157 2026 · Frontiers in Endocrinology | observational | supports | low | Narrative review of metabolic surgery techniques for T2DM, summarizing comparative efficacy, predictors of outcome, and long-term postoperative effectiveness; not a systematic review/meta-analysis by explicit methodology. |
| Pedarnig L et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=111 patients aged >=65, Vienna, 5yr follow-up. Prevalence of type 2 diabetes decreased from 54.1% to 22.9% after MBS. |
| Moioli D et al 2026 · study_type: observational | observational | supports | low | Retrospective single-center cohort, n=30 (SASI as redo/revisional surgery after failed primary procedures), 12-month follow-up. T2DM remission rates 'markedly improved' with near-complete resolution of comorbidities at 12 months (no exact % |
| Afzal 2025 · Cureus | meta-analysis | supports | moderate | Systematic review of 10 RCTs found bariatric surgery consistently outperforms medical therapy for durable diabetes remission and glycemic control. |
| Kirwan 2022 · Diabetes Care | RCT | supports | high | ARMMS-T2D consortium design/early data: metabolic surgery durably superior to medical/lifestyle for remission. |
| Zhen XM et al 2026 · study_type: observational | observational | mixed | moderate | Cohort, n=80 (44 young-onset, 36 older-onset T2DM), Australia, 12-month follow-up after metabolic surgery. Complete remission markedly lower in young-onset T2DM (38.1%) vs older-onset (75.0%, p=0.002), though difference not significant afte |
| Jaworski P et al 2026 · study_type: observational | observational | supports | moderate | Multicenter retrospective cohort (BARI-10-POL), n=113, Poland, 10-year follow-up (median 10.9yr). T2DM remission in 70.8%, improvement in 16.8%, no change in 12.4%; longer diabetes duration predicted lower remission. |
| Velji-Ibrahim J et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Network meta-analysis of 15 RCTs, n=1548 adults, >=52 weeks follow-up, comparing bariatric surgery (RYGB, LSG, GCP, LAGB) and bariatric endoscopy. RYGB and LSG (surgical arms) achieved significant T2DM remission alongside ESG. |
| d10-1093-bjs-znag063-123 2026 · British journal of surgery | meta-analysis | supports | moderate | Systematic review (PRISMA) of 33 studies (RCTs and cohorts), PubMed/Embase/Cochrane 2005-2024. Remission rates 60-80% for RYGB and 50-70% for sleeve gastrectomy vs lower for gastric banding; earlier disease stage and younger age associated |
| Schauer 2017 · N Engl J Med | RCT | supports | high | STAMPEDE 5yr RCT: HbA1c<=6.0% in 29% (bypass)/23% (sleeve) vs 5% medical; durable glycemic superiority. |
| Martínez-Montoro JI et al 2026 · study_type: observational | observational | supports | moderate | Retrospective two-center cohort, n=145 adults with T2D undergoing bariatric surgery, 1-year follow-up. Lower liver fibrosis risk score (HFS<.12) associated with 73.6% diabetes remission vs 52.1% in higher-risk group (RR=1.41). |
| Boutros T et al 2026 · study_type: observational | observational | mixed | moderate | Retrospective cohort, n=1323 with initial ORMC remission, primary MBS 2008-2022, >=36mo follow-up. T2D recurrence occurred in 16.2% of patients who had initially remitted; recurrence driven more by baseline severity/insulin dependence than |
| Sanchez-Cordero S et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Systematic review (PRISMA) of 7 studies, n=3735 with 5-year follow-up, OAGB as primary procedure. Pooled 5-year T2D remission rate 77.4%; authors note evidence remains limited/heterogeneous. |
| Mingrone 2021 · Lancet | RCT | supports | high | 10yr RCT: 37.5% surgical patients maintained diabetes remission vs 5.5% medical; relapse occurred but durable advantage held. |
| Courcoulas 2024 · JAMA | RCT | supports | high | Pooled 4-RCT ARMMS-T2D: at 7yr diabetes remission 18.1% surgery vs 6.2% medical; effect attenuates over time. |
| Teshaev O et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=127 (OAGB), 10-year follow-up with 100% retention. Complete T2DM remission (ADA criteria) achieved in 94.5% (120/127); all insulin-dependent patients discontinued insulin. |
| Abou-Sleiman R et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=226, public hospital Queensland, 2-year follow-up (96.9% retained). Complete diabetes remission achieved in 54.8% of patients at 2 years; 65% required insulin preoperatively. |
| Celik Esmer 2026 · Obes Surg | meta-analysis | supports | high | Network meta-analysis of 11 RCTs found all bariatric procedures significantly increased T2D remission versus medical/lifestyle therapy. |
| Kopanos S et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review and meta-analysis, 29 studies, n=71,904 with MAFLD undergoing bariatric surgery. Pooled T2D remission rate 59%, alongside 70% steatohepatitis and 57% fibrosis remission. |
| Alum EU et al 2026 · study_type: observational | observational | supports | low | Narrative review of gut microbiome-derived metabolites as predictors of bariatric surgery outcomes including T2DM remission; higher beneficial metabolite levels associated with greater remission likelihood, though evidence inconsistent acro |
| Takano H et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort, n=90 (LSG), Japan, 6-month follow-up. T2D remission/improvement rate was 75%; higher skeletal muscle mass associated with remission. |
| Ikramuddin 2016 · Diabetes Care | RCT | supports | moderate | Adding Roux-en-Y gastric bypass to lifestyle-medical management achieved treatment goals more often at 3 years in uncontrolled T2D. |
| Tan SYT et al 2026 · study_type: observational | observational | supports | low | Cohort, n=184 (BMI>=50, Asian), 24-month follow-up. Diabetes remission rates 69.2% at 12 months and 76.7% at 24 months, no significant difference between gastric bypass and sleeve gastrectomy. |
| Susmallian S et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=60, BMI>=60, up to 10yr follow-up (mean 72mo). T2D remission/improvement occurred in 77.8% of patients despite frequent long-term weight regain. |
| Leyaro B et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=186 (SG/RYGB), UK. Remission rates 57.5% at 2yr and 36.4% at 5yr; of those remitted at 2yr, 33.4% relapsed by 5yr. |
| Mendes C et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort, n=81 RYGB patients, Portugal, 5-year follow-up. T2DM remission/improved control in 66.7% of diabetic patients at 5 years despite frequent weight regain. |
| Si Y et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, n=75, 1-year follow-up. Early reduction in serum clusterin independently predicted T2D remission (defined as HbA1c<5.7% + fasting glucose<5.6mmol/L off medication), partially mediated by improved insulin sensitivity. |
| Sjostrom 2014 · JAMA | observational | supports | high | SOS: 2yr remission 72% vs 16% controls, falling to 30.4% vs 6.5% at 15yr—remission real but relapses. |
| Olsson LM et al 2026 · study_type: RCT | observational | supports | moderate | Subanalysis of the randomized Oseberg trial (RYGB n=39, SG n=38), 12-month microbiome profiling with 5-year T2D remission linkage. Surgery-induced microbiome changes correlated with GLP-1, beta-cell function, and 5-year T2D remission, indep |
| Czerwińska A et al 2026 · study_type: observational | observational | supports | moderate | Retrospective multicenter cohort, n=89 (BMI>=50 subgroup), mean 11.1yr follow-up (BARI-10-POL). T2DM remission rate 59.1% at long-term follow-up, comparable between BMI subgroups. |
| Lee Y et al 2026 · study_type: observational | observational | supports | moderate | Multicenter retrospective cohort, n=410 East Asian patients, 12-month follow-up. T2DM remission rates 47.6% (>=55yo) vs 80.5% (<55yo), both demonstrating meaningful metabolic improvement. |
| Choi SI et al 2026 · study_type: observational | observational | supports | moderate | Prospective multicenter cohort, n=116, Korea, up to 2-year follow-up. T2DM remission rates 80.7% at 1 year, increasing to 85.7% at 2 years. |
| Sjoholm 2016 · Diabetes Care | observational | supports | moderate | SOS: gastric bypass improved glucose/insulin/HOMA-IR partly independent of weight change at 2 and 10yr. |
| Abdulrazzaq S et al 2026 · study_type: observational | observational | supports | moderate | Prospective cohort, n=48 (sleeve gastrectomy), 5-year follow-up. T2DM remission rate 71.4%; cardiometabolic and OSA benefits retained even in patients with weight regain (~31%). |
| Guo H et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort, n=60 adolescents (Grade IV/V obesity) undergoing LSG, 31 completed 1-year follow-up. All patients with preoperative T2DM (8/8) achieved remission criteria at 1 year. |
| Jiao Y et al 2026 · Scientific Reports | animal | supports | low | Rat model of obese T2DM (sleeve gastrectomy vs sham). SG significantly reduced fasting glucose and insulin resistance versus sham, via IL-27/p38 MAPK/PGC-1alpha pathway in adipose tissue. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.